

Morten Ladekarl Klinisk Professor, overlæge, Dr. Med. Aalborg  
Universitetshospital Klinisk Institut Det Sundhedsvidenskabelige Fakultet Klinik  
Kirurgi og Kræftbehandling Kræftbehandling (Onkologi) E-mail:  
morten.ladekarl@rn.dk, mla@dcm.aau.dk

## **Ansættelse**

**Aalborg Universitetshospital**  
Det Sundhedsvidenskabelige Fakultet  
1 jan. 2019 → present

**Klinisk Professor**  
Klinisk Institut  
Det Sundhedsvidenskabelige Fakultet  
Gistrup, Danmark  
1 jan. 2019 → present

**Klinisk Professor**  
Det Sundhedsvidenskabelige Fakultet  
Gistrup, Danmark  
1 jan. 2019 → present

**Det Sundhedsvidenskabelige Fakultet**  
Gistrup, Danmark  
1 jan. 2019 → present

**Professor**  
Afdeling for Kræftbehandling  
Det Sundhedsvidenskabelige Fakultet  
1 jan. 2019 → present

## **Publikationer**

**TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trial**

Bæksgaard Jensen, L., Yilmaz, M., Nordmark, M., Möller, S., Elle, I. C., Ladekarl, M., Qvortrup, C. & Pfeiffer, P., apr. 2024, I: EClinicalMedicine. 70, 10 s., 102521.

**Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation**

Kirkegård, J., Ladekarl, M., Lund, A. & Mortensen, F., feb. 2024, I: Annals of Surgical Oncology. 31, 2, s. 1310-1318 9 s.

**Germline variants in patients with end-stage cancer**

Lundsgaard, M., Mapendano, C., Sønderkær, M., Ernst, A., Pedersen, I. S., Nohr, A. K., Ladekarl, M. & Sunde, L., 8 jan. 2024, I: European Journal of Human Genetics. 32, Suppl. 1, s. 557 1 s., P13.039.C.

**Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation**

Kirkegård, J., Ladekarl, M., Johannsen, I. R. & Mortensen, F., 3 jan. 2024, I: British Journal of Surgery. 111, 1, znad398.

**Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms**

Mørken, S., Langer, S. W., Sundlöv, A., Vestermark, L. W., Ladekarl, M., Hjortland, G. O., Svensson, J. B., Tabaksblat, E. M., Haslerud, T. M., Assmus, J., Detlefsen, S., Couvelard, A., Perren, A. & Sorbye, H., 7 dec. 2023, I: British Journal of Cancer. 129, 12, s. 1930-1939 10 s.

**Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms**  
Venizelos, A., Sorbye, H., Elvebakken, H., Perren, A., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., Sundlöv, A., Svensson, J., Garresori, H., Kersten, C., Hofslie, E., Detlefsen, S., Vestermark, L. W., Ladekarl, M., Tabaksblat, E. M. & Knappskog, S., 1 okt. 2023, I: Endocrine-Related Cancer. 30, 10, 12 s., e230057.

**ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer**  
Ladekarl, M., Shim, S., Ettrich, T. J., Kestler, A., Pfeiffer, P., Tarpgaard, L. S., Reinacher-Schick, A., Kraeft, A-L., Stenvang, J., Zurlo, A. & Roest, N. L., okt. 2023, I: Annals of Oncology. 34, Suppl. 2, s. S907 1 s., 1641P.

**Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors**  
Mouritzen, M. T., Ladekarl, M., Hager, H., Mattesen, T. B., Lippert, J. B., Frank, M. S., Nøhr, A. K., Egendal, I. B. & Carus, A., 8 sep. 2023, I: Cancers. 15, 18, s. 4480 4480.

**Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab**  
Nowicka-Matus, K., Salkus, G., Sønderkær, M., Søkilde Pedersen, I., Ernst, A., Kubik, M., Takacs-Szabo, Z. & Ladekarl, M., 18 aug. 2023, I: JCO Precision Oncology. 7, e2300173.

**A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)**  
Rasmussen, L. S., Winther, S. B., M. Chen, I., Weber, B., Ventzel, L., Liposits, G., Johansen, J. S., Detlefsen, S., Egendal, I., Shim, S., Christensen, S., Pfeiffer, P. & Ladekarl, M., 16 jun. 2023, I: BMC Cancer. 23, 1, 552.

**Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?**  
Ladekarl, M., apr. 2023, I: Chinese clinical oncology. 12, 2, s. 10 1 s., 10.

**Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital**  
Ladekarl, M., Nøhr, A. K., Sønderkær, M., Dahl, S. C., Sunde, L., Vestereghem, C., Mapendano, C. K., Haslund, C. A., Pagh, A., Carus, A., Lörincz, T., Nowicka-Matus, K., Poulsen, L. Ø., Laursen, R. J., Dybkær, K., Poulsen, B. K., Frøkjær, J. B., Brügmann, A. H., Ernst, A., Wanders, A., & 2 flereBøgsted, M. & Pedersen, I. S., mar. 2023, I: Acta Oncologica. 62, 3, s. 261-271 11 s.

**ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial**  
Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B. E., Ladekarl, M., Haslund, C. A., Harsløf, L., Belcaid, L., Gehl, J., Søndergaard, L., Eefsen, R. L., Hansen, K. H., Kodahl, A. R., Jensen, L. H., Holt, M. I., Oellegaard, T. H., Yde, C. W., Ahlborn, L. B. & Lassen, U., 22 feb. 2023, I: BMC Cancer. 23, 1, 12 s., 182.

**Pd-L1 Blockade Followed by Irreversible Electroporation of a Liver Metastasis in Pancreatic Cancer Patients**  
Flak, R. V., Kofod-Olsen, E., Sølvsten, N. D., Naujokaitė, G., Agger, R., Stender, M. T., Christensen, S., Shim, S., Poulsen, L. Ø., Detlefsen, S., Thorlasius-Ussing, O. & Ladekarl, M., 2023, SSRN: Social Science Research Network, 19 s.

**Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?**  
Abo, C., Krastrup, T. W., Tenstad, H. B., Ren, J., Just, S. A., Ladekarl, M. & Stensballe, A., 22 dec. 2022, I: Expert Review of Precision Medicine and Drug Development. 7, 1, s. 162-168

**Onkologisk behandling – af cancer pancreatis**  
Ladekarl, M., Weber, B., Jensen, B. V. & Pfeiffer, P., 1 jul. 2022, Version 1.2 udg. Danske Multidisciplinære Cancer Grupper. 27 s.

**O-4 Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophago-gastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas)**

Pfeiffer, P., Yilmaz, M., Nordmark, M., Möller, S., Elle, I., Ladekarl, M., Winther, S., Qvortrup, C. & Baeksgaard, L., jun. 2022, I: Annals of Oncology. 33, Suppl. 4, s. S380

**Implementing a data infrastructure for precision oncology projects leveraging REDCap**

Vesteghem, C., Dahl, S. C., Brøndum, R. F., Sønderkær, M., Bødker, J. S., Schmitz, A., Weischenfeldt, J., Pedersen, I. S., Sommer, M., Rytter, A. S., Nielsen, M. M., Ladekarl, M., Severinsen, M. T., Dybkær, K., Grønbæk, K., El-Galaly, T., Roug, A. S. & Bøgsted, M., 12 maj 2022, medRxiv, 20 s. (medRxiv).

**Dansk Pancreas Cancer Database (DPCD) – Resumé af Årsrapport 2020/2021**

Styregruppen & Ladekarl, M., 24 jan. 2022, I: Ugeskrift for Laeger. 2 s.

**Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study**

Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., & 7 flereHomann, P. H., Kristensen, E. B., Drivsholm, L. B., Bøgsted, M., Christensen, H. S., Pøhl, M. & Bjørnhart, B., 2022, I: Acta Oncologica. 61, 4, s. 409-416 8 s.

**Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer**

Ladekarl, M., Rasmussen, L. S., Kirkegård, J., Chen, I., Pfeiffer, P., Weber, B., Skuladottir, H., Østerlind, K., Larsen, J. S., Mortensen, F. V., Engberg, H., Möller, H. & Fristrup, C. W., 2022, I: Acta Oncologica. 61, 3, s. 277-285 9 s.

**Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI. Journal of Clinical Oncology**

Schou, J. H. V., Roest, N., Ladekarl, M., Hansen, J. B. R., Hedtjaern, M. & Vestlev, P. M., 2022, I: Journal of Clinical Oncology. 40, Suppl. 4, 1 s., 185.

**Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer**

Steiniche, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Tang, L. H., Wu, T., Marton, M. J., Peter, S., Kelsen, D. P. & Ku, G., dec. 2021, I: Cancer Medicine. 10, 23, s. 8365-8376 12 s.

**Merkelcelle hudkræft**

Naseri, S., Fagmedarbejdere, Naseri, S., Chakera, A. H., Steiniche, T., Ladekarl, M., Mogensen, M. & Kjeldsen, H. C., 17 nov. 2021, sundhed.dk.

**Merkelcelle karcinom**

Fagmedarbejdere, Naseri, S., Chakera, A. H., Steiniche, T., Ladekarl, M., Mogensen, M. & Kjeldsen, H. C., 17 nov. 2021, sundhed.dk.

**Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy**

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Frary, J. M. C., & 5 flereDrivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 28 sep. 2021, I: Cancers. 13, 19, 4846.

**Clinically decisive (dis)agreement in multidisciplinary team assessment of esophageal squamous cell carcinoma; a prospective, national, multicenter study**

Achiam, M. P., Nordmark, M., Ladekarl, M., Olsen, A., Loft, A., Garbyal, R. S., Larsen, M. H., Ainsworth, A. P., Kristensen, T. S., Dikinis, S., Kjær, D. W., Bæksgaard, L., Siemsen, M., Nielsen, M. B., Schlander, S., Kramer, S., Katballe, N., Kruhlkava, I., Tabaksblat, E., Fisker, R. V., & 6 flereMortensen, P. B., Holtved, E., Eckardt, J., Detlefsen, S., Naujokaite, G. & Lütken, C. D., sep. 2021, I: Acta Oncologica. 60, 9, s. 1091-1099 9 s.

**Folirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas**

Butt, B. P., Stokmo, H. L., Ladekarl, M., Tabaksblat, E. M., Sorbye, H., Revheim, M. E. & Hjortland, G. O., sep. 2021, I: Annals of Oncology. 32, 5, s. S915-S915 1108P.

**Merkelcellekarcinom**

Naseri, S., Steiniche, T., Ladekarl, M., Hölmich, L. R., Langer, S. W., Tabaksblat, E. M., Junker, N. & Chakera, A. H., 26 jul. 2021, I: Ugeskrift for Laeger. 183, 3 s., V03210260.

**Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma**

Dyhl-Polk, A., Mikkelsen, M. K., Ladekarl, M. & Nielsen, D. L., 16 jun. 2021, I: Journal of Clinical Medicine. 10, 12, 2662.

**Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study**

Rasmussen, L. S., Fristrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Bøgsted, M. & Falkmer, U. G., 22 maj 2021, I: Pancreas. 50, 5, s. 685-695 11 s.

**Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms**

Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E. M., Vestermark, L. W., Janson, E. T., Hansen, C. P., Ladekarl, M., Garresori, H., Hjortland, G. O., Sundlöv, A., Galleberg, R., Knigge, P., Kjaer, A., Langer, S. W. & Knigge, U., maj 2021, I: Journal of Neuroendocrinology. 33, 5, e12967.

**A phase II-study of electroporation potentiated immunotherapy in liver metastatic pancreatic cancer (EPIC-1)**

Flak, R. V., Poulsen, L. Ø., Stender, M. T., Naujokaite, G., Tcacenco, O., Wanders, A., Detlefsen, S., Agger, R., Kofod-Olsen, E., Thorlacius-Ussing, O. & Ladekarl, M., 2021, *Danske Kræftforskningsdage: Abstract Book*. s. 51 40

**Beskrivelse af den nationale MDT konference for pancreascancer: deltagelse og tilbud om operation**

Engberg, H., Møller, H., Hansen, C. P., Burgdorf, S., Fallentin, E., Fristrup, C. W., Jensen, B. V., Jensen, J. W., Knudsen, A. R., Ladekarl, M., Larsen, L. P. S., Mortensen, F. V., Kissmeyer-Nielsen, P., Sall, M., Stender, M. T., Storkholm, J. H., Gyllenborg, J. & Hillingsø, J., 2021, *Danske Kræftforskningsdage: Abstract Book*. s. 164 145

Hans Jørgen Gottlieb Gundersen: 2.5.1943-1.2.2021

Nyengaard, J. R., Ladekarl, M., Dorph-Petersen, K-A., Bendtsen, T. F., Nielsen, K. & Sørensen, F. B., 2021, I: Ugeskrift for Laeger.

**Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy**

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Frary, J. M. C., & 5 flereDrivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 2021.

**Scrotal Paget's disease associated with metastatic carcinoma with apocrine features and ERBB2-amplification/HER2 overexpression responding well to weekly paclitaxel combined with trastuzumab and pertuzumab. A case report**

Nowicka-Matus, K., Salkus, G., Pedersen, I. S., Sønderkær, M., Ernst, A., Takacs-Szabó, Z. & Ladekarl, M., 2021, *Danske Kræftforskningsdage: Abstract Book*. s. 152 133

**Udredning og behandling af Cholangiocarcinom**

Larsen, P. N. (red.), Rasmussen, A., Schultz, N., Mortensen, F. V., Knudsen, A. R., Stender, M. T., Sall, M., Pless, T., Vistisen, K., Larsen, F. O., Weber, B., Mortensen, H. R., Boysen, A. K., Ladekarl, M., Risum, S., Jensen, L. H., Fallentin, E., Willemoe, G., Hamilton, S., Kjær, M., & 4 flereGrønbæk, H., Villadsen, G., Loft, A. & Schultz, L., 27 okt. 2020, Version 1.0 udg. Danske Multidisciplinære Cancer Grupper. 72 s.

**Oncological treatment - of cancer pancreatis**

Ladekarl, M., Weber, B., Jensen, B. V. & Pfeiffer, P., 16 okt. 2020, Version 1.0 udg. Danske Multidisciplinære Cancer Grupper. 24 s.

**PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy**

Steinicke, T., Marsico, M. A., Siegel, A. B., Gronbaek, H., Ha, S., Hong, J. Y., Paik, Y-H., Georgsen, J., Pommergaard, H-CL., Ladekarl, M., Webber, A., Liu, X., Kachurak, A., Skaarup, K., Lee, J. & Lim, H. Y., 1 sep. 2020, I: Annals of Oncology. 31, Suppl. 4, s. S697 1006P.

**Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort**

Mouritzen, M., Bjoernhart, B., Poehl, M., Ladekarl, M., Vesteghem, C., Boegsted, M., Nielsen, A. W. M., Meldgaard, P., Hansen, K. H., Larsen, J. W. W., Kristiansen, C., Wedervang, K., Bareid-Oestby, A-C., Frank, M. S., Persson, G., Kristensen, E. B., Homann, P. H. & Carus, A., 1 sep. 2020, I: Annals of Oncology. 31, Suppl. 4, s. S858 1 s., 1334P .

**Targeting anti-cancer drug resistance in gastro-intestinal cancer: Inhibition of the SRPK1 kinase and degradation of the ABCG2 drug efflux pump**

Ladekarl, M., Schou, J. H. V., Roest, N. L., Stenvang, J., Brünner, N. & Vestlev, P. M., 1 sep. 2020, I: Annals of Oncology. 31, Suppl. 4, s. S503-S504 2 s., 605TiP .

**Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers**

Steinicke, T., Ladekarl, M., Georgsen, J. B., Andreasen, S., Busch-Sorensen, M., Zhou, W., Marton, M. J., Pruitt, S. K., Jin, F. & Liaw, K-L., 19 aug. 2020, I: Future Science OA. 6, 8, 11 s., FSO616.

**International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis**

Díaz-González, Á., Sanduzzi-Zamparelli, M., Gomes da Fonseca, L. L., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C., Sacco, R., Matilla, A. M., Hernández-Guerra, M., Aballay Soteras, G., Wörns, M-A., Pinter, M., Varela, M., Ladekarl, M., Chagas, A. L., Minguez, B., Arenas, J. I., Granito, A., Sánchez-Torrijos, Y., & 29 flereRojas, Á., Rodríguez de Lope, C., Alvares-da-Silva, M. R., Pascual, S., Rimassa, L., Lledó, J. L., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara, M., Perelló, C., Lue, A., Sala, M., Gallego, A., Coll, S., Hernández, T., Piñero, F., Pereira, G., França, A., Marín, J., Anders, M., Mello, V., Lozano, M., Nault, J. C., Menéndez, J., García Juárez, I., Bruix, J. & Reig, M., jun. 2020, I: Liver International. 40, 6, s. 1467-1476 10 s.

**Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma**

Naseri, S., Steiniche, T., Georgsen, J. B., Thomsen, R., Ladekarl, M., Heje, M., Damsgaard, T. E. & Bønnelykke-Behrndtz, M. L., 6 apr. 2020, I: Cancers. 12, 4, s. 1-11 11 s., 888.

**Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study**

Rasmussen, L. S., Fristrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., Sall, M., Detlefsen, S., Bøgsted, M. & Falkmer, U. G., apr. 2020, I: European Journal of Cancer. 129, s. 50-59 10 s.

**Pilot study experiences with hyperpolarized [1-13 C]pyruvate MRI in pancreatic cancer patients**

Stødkilde-Jørgensen, H., Laustsen, C., Hansen, E. S. S., Schulte, R., Ardenkjær-Larsen, J. H., Comment, A., Frøkjaer, J., Ringgaard, S., Bertelsen, L. B., Ladekarl, M. & Weber, B., mar. 2020, I: Journal of Magnetic Resonance Imaging. 51, 3, s. 961-963 3 s.

**Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis**

Kirkegård, J., Gaber, C., Lund, J. L., Hinton, S. P., Ladekarl, M., Heide-Jørgensen, U., Cronin-Fenton, D. & Mortensen, F. V., feb. 2020, I: Cancer epidemiology. 64, 9 s., 101647.

**Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective**

Naseri, S., Steiniche, T., Ladekarl, M., Bønnelykke-Behrndtz, M. L., Hölmich, L. R., Langer, S. W., Venzo, A., Tabaksblat, E., Klausen, S., Skaarup Larsen, M., Junker, N. & Chakera, A. H., feb. 2020, I: Cancers. 12, 3, 13 s., 554.

**PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3**

Ali, A. S., Langer, S. W., Federspiel, B., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Welin, S., Weber Vestermark, L., Arola, J., Österlund, P., Knigge, U., Sørbye, H., Micke, P., Grimelius, L., Grönberg, M. & Tiensuu Janson, E., 2020, I: PLOS ONE. 15, 12, e0243900.

Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients  
Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E., Vestermark, L., Tiensuu Janson, E., Hansen, C. P., Ladekarl, M., Garresori, H., Langer, S. & Knigge, U., 2020, *17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, 11-13 March 2020, Barcelona, Spain, Virtual Conference*. s. 319

Impact of Concurrent Acute Pancreatitis on Pancreatic Cancer Stage, Treatment, and Prognosis: A Study of Two Cohorts  
Kirkegård, J., Gaber, C., Lund, J. L., Peacock-Hinton, S., Ladekarl, M., Heide-Jørgensen, U., Cronin Fenton, D. & Mortensen, F. V., 3 jun. 2019.

**The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study**

Skau Rasmussen, L., Vittrup, B., Ladekarl, M., Pfeiffer, P., Karen Yilmaz, M., Østergaard Poulsen, L., Østerlind, K., Palnæs Hansen, C., Bau Mortensen, M., Viborg Mortensen, F., Sall, M., Detlefsen, S., Bøgsted, M. & Wilki Fistrup, C., jun. 2019, I: *Acta Oncologica*. 58, 6, s. 864-871 8 s.

**A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis**

Diaz-Gonzalez, A., Sanduzzi-Zamparelli, M., Gomes da Fonseca, L., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C. R. G., Sacco, R., Matilla, A. M., Guerra, M. H., Aballay Soteras, G. A., Marcus, W., Pinter, M., Varela, M., Ladekarl, M., Lopes Chagas, A., Minguez, B., Ignacio Arenas Ruiz-Tapiador, J., Granito, A., Sánchez, Y., & 29 flereRojas, A., Rodriguez De Lope, C., Reis Álvares-Da-Silva, M., Pascual, S., Rimassa, L., Luis Lledó, J., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara Gómez, M., Perello, C., Lué, A., Sala, M., Gallego Moya, A., Coll, S., Hernaez Alsina, T., Pinero, F., Pereira, G., Vianey Callado França, A., Callado França, V., Margarita Anders, M., Mello, V., Del Mar Lozano, M., Charles Nault, J., María Menéndez, J., Garcia Juarez, I., Bruix, J. & Reig, M., apr. 2019, I: *Journal of Hepatology*. 70, 1S, s. E599-E600 FRI-462.

Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature

Overby, A., Duval, L., Ladekarl, M., Laursen, B. E. & Donskov, F., feb. 2019, I: *Clinical genitourinary cancer*. 17, 1, s. e32-e37 6 s.

T-cell-inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).  
Steinicke, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Wu, T., Savage, M. J., Marton, M. J., Kang, S. P., Peter, S. A., Kelsen, D. P. & Ku, G. Y., 2019, I: *Journal of Clinical Oncology*. 37, Suppl. 4, s. 26 1 s.

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Ali, A. S., Grönberg, M., Langer, S. W., Ladekarl, M., Hjortland, G. O., Vestermark, L. W., Österlund, P., Welin, S., Grønbæk, H., Knigge, U., Sørbye, H. & Janson, E. T., 6 mar. 2018, I: *Medical Oncology*. 35, 4, s. 47

Effects of Cyoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study

Madsen, A. H., Ladekarl, M., Villadsen, G. E., Grønbæk, H., Sørensen, M. M., Stribolt, K., Verwaal, V. J. & Iversen, L. H., feb. 2018, I: *Annals of Surgical Oncology*. 25, 2, s. 422-430 9 s.

Association of PD-L1 expression with prognosis among patients with 10 select cancers

Steinicke, T., Ladekarl, M., Bæhr Georgsen, J., Andreasen, S., Busch-Sørensen, M., Zhou, W., Pruitt, S. K., Joe, A. K. & Liaw, K-L., 2018, I: *Annals of Oncology*. 29, Suppl. 8, s. viii15 53PD.

**Geographical Residency Influences Pancreatic Cancer Survival: A Danish Nationwide Population-based Cohort Study**  
Kirkegård, J., Ladekarl, M., Fristrup, C., Hansen, C. P., Sall, M. & Mortensen, F. V., 2018.

**Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study**  
Kirkegård, J., Ladekarl, M., Fristrup, C. W., Hansen, C. P., Sall, M. & Mortensen, F. V., 2018, I: PLOS ONE. 13, 8, 11 s., e0202486.

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Galleberg, R. B., Knigge, U., Tiensuu Janson, E., Vestermark, L. W., Haugvik, S-P., Ladekarl, M., Langer, S. W., Grønbæk, H., Österlund, P., Hjortland, G. O., Assmus, J., Tang, L., Perren, A. & Sorbye, H., sep. 2017, I: European Journal of Surgical Oncology. 43, 9, s. 1682-1689 8 s.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Ali, A. S., Grönberg, M., Federspiel, B., Scoazec, J-Y., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Langer, S. W., Welin, S., Vestermark, L. W., Arola, J., Österlund, P., Knigge, U., Sorbye, H., Grimelius, L. & Janson, E. T., 2017, I: PLoS One. 12, 11, 15 s., e0187667.

Danish Pancreatic Cancer Database

Fristrup, C., Detlefsen, S., Hansen, C. P. & Ladekarl, M., 25 okt. 2016, I: Clinical Epidemiology. 8, s. 645-648 4 s.

Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art

Tabaksblat, E. M., Langer, S. W., Knigge, U., Grønbæk, H., Mortensen, J., Petersen, R. H., Federspiel, B. H. & Ladekarl, M., jan. 2016, I: Acta Oncologica. 55, 1, s. 3-14 12 s.

BRCA-associated pancreatico-biliary neoplasms: four cases illustrating the emerging clinical impact of genotyping

Sharma, M. B., Carus, A., Sunde, L., Hamilton-Dutoit, S. & Ladekarl, M., 2016, I: Acta Oncologica. 55, 3, s. 377-381 5 s.

**A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic Factors**

Larsen, A. C., Holländer, C., Duval, L., Schönnemann, K., Achiam, M., Pfeiffer, P., Yilmaz, M. K., Thorlacius-Ussing, O., Bæksgaard, L. & Ladekarl, M., 2015, I: Annals of Surgical Oncology. 22, 5, s. 1540-1547

Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients

Olsen, I. H., Holt, N., Langer, S. W., Hasselby, J. P., Grønbæk, H., Hillingsø, J., Mahmoud, M., Ladekarl, M., Iversen, L. H., Kjær, A., Federspiel, B. H. & Knigge, U., 2015, I: PLOS ONE. 10, 2, s. e0117627

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jäntti, C., Sundin, A., Sundlöv, A., Thils-Evensen, E. & Knigge, U., okt. 2014, I: Acta oncologica (Stockholm, Sweden). 53, 10, s. 1284-97 14 s.

Postoperative but not preoperative treatment with Sorafenib inhibits liver regeneration in rats

Andersen, K. J., Knudsen, A. R., Kannerup, A-S., Nyengaard, J. R., Hamilton-Dutoit, S. J., Ladekarl, M. & Mortensen, F. V., 15 apr. 2014.

Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer  
Kraemer, P. C., Schmidt, H. H. & Ladekarl, M., apr. 2014, I: Danish Medical Journal. 61, 4, A4819.

**Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments**

Carus, A., Donskov, F., Switten Nielsen, P., Hager, H., Nedergaard, B., Steiniche, T. & Ladekarl, M., 2014, I: The Journal of OncoPathology. 2, 2, s. 1-9 9 s.

**Tumour-associated CD66b + neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer**

Carus, A., Ladekarl, M., Hager, H., Nedergaard, B. & Donskov, F., 1 maj 2013, I: British Journal of Cancer. 108, 10, s. 2116-2122 7 s.

Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: A case description  
Ladekarl, M., Villadsen, G. E., Rudbeck, A. R., Aagenæs, Ø., Nielsen, J. E., Hamilton-Dutoit, S. & Nordmark, M., 1 jan. 2013, I: Case Reports in Oncology. 6, 1, s. 98-103 6 s.

Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger og GH-receptorantagonist til akromegali.  
Hangaard, J., Andersen, M., Laursen, T., Nielsen, E. H., Storm, T. L., Rasmussen, Å. K., Poulsen, P. L., Friberg, A., Ladekarl, M., Schaffalitzky de Muckadell, O. B., Wilson, B., Knigge, U. P. & Grønbæk, H., 2013, *Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger og GH-receptorantagonist til akromegali..*

Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger til neuroendokrine tumorer

Knigge, U. P., Grønbæk, H., Ladekarl, M., Schaffalitzky de Muckadell, O. B., Wilson, B., Hangaard, J., Andersen, M., Laursen, T., Friberg, A., Nielsen, E. H., Storm, T. L., Rasmussen, Å. K. & Poulsen, P. L., 2013, *Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger til neuroendokrine tumorer.* 13 s.

Diffuse abdominal splenosis mimicking peritoneal metastases in a 35-year-old man with a resectable carcinoma of the ampulla of vater

Sorensen, S. F., Mortensen, F. V., Hellberg, Y. & Ladekarl, M., 2013, I: Case Reports in Oncology. 6, 3, s. 467-71 5 s.

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., Maase, H. V. D. & Donskov, F., 2013, I: Journal of Translational Medicine. 11, 8, 10 s., 189.

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability

Køstner, A. H., Sørensen, M., Olesen, R. K., Grønbæk, H., Lassen, U. & Ladekarl, M., 2013, I: Scientific World Journal. 2013, s. 931972

Sorafenib inhibits liver regeneration in rats

Andersen, K. J., Knudsen, A. R., Kannerup, A-S., Sasanuma, H., Nyengaard, J. R., Hamilton-Dutoit, S. J., Ladekarl, M. & Mortensen, F. V., 2013.

**Tumor-associated CD66b+neutrophil and CD8+lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments**

Carus, A., Ladekarl, M., Nielsen, P. S., Hager, H., Nedergaard, B. S., Steiniche, T. & Donskov, F., 2013, I: Journal of Clinical Oncology. 31, 15, suppl.

Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome  
Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Switten Nielsen, P. & Donskov, F., 2013, I: Lung Cancer. 81, 1, s. 130-137 8 s.

Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage

Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Switten Nielsen, P. & Donskov, F., 2012, I: Journal of Clinical Oncology. 30, Suppl. 15, 1 s., e21110.

Dansk Pancreas Cancer Database

Fistrup, C., Palnæs Hansen, C., Ladekarl, M. & Mortensen, M. B., 2012, I: Ugeskift for Læger. 174, 42, s. 2545 1 s.

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers  
Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Pappot, H., Christensen, I. J., Høyer-Hansen, G., Sørensen, M., Skov, B. G., Buysschaert, I., Carmeliet, P. & Lassen, U., 2012, I: *Acta Oncologica*. 51, 2, s. 234-42 9 s.

Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs  
Zukauskaite, R., Hjorthgau, K., Poulsen, P. L., Baerentzen, S. & Ladekarl, M., 30 jun. 2011, I: *Acta Oncologica*. 50, 8, s. 1255-9 5 s.

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab  
Rohrberg, K. S., Pappot, H., Lassen, U., Westman, M., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Sørensen, M., Christensen, I. J. & Skov, B. G., 2011, I: *Cancer Biology & Therapy*. 11, 8, s. 732-9 8 s.

Ovariemetastaser fra ventrikeltcancer diagnosticeret med diffusionsvægtet 3T-magnetisk resonans-skanning  
Røhl, L., Nellemann, H. M., Ladekarl, M. & Pedersen, E. M., 2011, I: *Ugeskrift for Laeger*. 173, 16-17, s. 1212-3 2 s.

Toxicity-adjusted dose (TAD) administration of chemotherapy: Effect of baseline and nadir neutrophil count in patients with breast, ovarian, and lung cancer?  
Carus, A., Donskov, F., Gebski, V., Kefford, R., Wilcken, N., Hui, R., Harnett, P., Ladekarl, M., Maase, H. V. D. & Gurney, H., 2011, I: *Journal of Clinical Oncology*. 29, Suppl. 15, 1 s., e21023.

Onkologisk behandling af patienter med pancreascancer  
Ladekarl, M., Jensen, B. V. & Pfeiffer, P., 3 maj 2010, I: *Ugeskrift for Laeger*. 172, 18, s. 1373-6 4 s.

A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years  
Nedergaard, B., Ladekarl, M., Nyengaard, J. R. & Nielsen, K., 2008, I: *Gynecologic Oncology*. 108, 1, s. 106-111 6 s.

Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer  
Nedergaard, B., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2008. 1 s.

Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer  
Nedergaard, B. S., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2007, I: *British Journal of Cancer*. 97, 8, s. 1135-1138 4 s.

Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri  
Nedergaard, B., Nielsen, K., Nyengaard, J. R. & Ladekarl, M., 2007, I: *Acta Pathologica Microbiologica et Immunologica Scandinavica*. 115, 12, s. 1321-30 9 s.

Choice of Methodology for Quantifying Cancer Structures in Tissue Sections: A Comparison of 2- and 3-Dimensional Estimators of Mitotic Activity, Cellularity and Nuclear Size in Breast Cancer  
Ladekarl, M., apr. 2004, I: *Analytical and quantitative cytology and histology*. 26, 2, s. 97-104 8 s.

Detection of circulating tumour lysate-reactive CD4+ T cells in melanoma patients  
Ladekarl, M., Agger, R., Fleischer, C. C., Hokland, M., Hulgaard, E. F., Kirkin, A., von der Maase, H., Petersen, M. S., Rytter, C., Zeuthen, J. & Gundersen, H. J. G., 2004, I: *Cancer Immunology, Immunotherapy*. 53, s. 560-566 7 s.

Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas  
Nordström, M., Lancaster, J., Aquino-Parsons, C., Chou, S-C., Ladekarl, M., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J. & Raleigh, J. A., apr. 2003, I: *Radiotherapy & Oncology*. 67, 1, s. 35-44 10 s.

Nye behandlingsperspektiver ved duktalt carcinoma in situ mammae: New therapeutic perspectives in breast ductal carcinoma in situ

Ladekarl, M., Grau, C. & Andersen, J., 2001, I: Ugeskrift for Laeger. 163, 37, s. 5014-5017 4 s., 4979.

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

Horsman, M. R., Ehrnrooth, E., Ladekarl, M. & Overgaard, J., 1 nov. 1998, I: International Journal of Radiation Oncology, Biology, Physics. 42, 4, s. 895-898 4 s.

Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas

Jensen, V., Sørensen, F. B., Bentzen, S. M., Ladekarl, M., Nielsen, O. S., Keller, J. & Jensen, O. M., jun. 1998, I: Histopathology. 32, 6, s. 536-46 11 s.

Objective malignancy grading: A review emphasizing unbiased stereology applied to breast tumors  
Ladekarl, M., 1998, I: APMIS, Supplement. 106, Suppl. 79, s. 5-34 30 s.

Total number of cancer cell nuclei and mitoses in breast tumors estimated by the optical disector

Ladekarl, M., Jensen, V. & Nielsen, B., aug. 1997, I: Analytical and quantitative cytology and histology. 19, 4, s. 329-337 9 s.

The prognostic value of MIB-2 and bcl-2 expression in soft tissue sarcomas.

Jensen, V., Sørensen, F. B., Ladekarl, M., Nielsen, O. S. & Jensen, O. M., mar. 1996.

The prognostic value of quantitative histopathology in soft tissue fibrosarcomas.

Ladekarl, M., Jensen, V., Sørensen, F. B., Nielsen, O. S. & Jensen, O. M., mar. 1996.

The prognostic value of quantitative histopathology in soft tissue malignant fibrous histiocytomas.

Sørensen, F. B., Jensen, V., Ladekarl, M., Nielsen, O. S. & Jensen, O. M., mar. 1996.

Objektiv histologisk gradering af planocellulaer og adenoskvamøs lungecancer

Ladekarl, M., Hansen, T. B., Nielsen, R. H., Mouritzen, C., Henriques, U. & Sørensen, F. B., 1996, I: Ugeskrift for læger. 158, 40, s. 5611-5615 5 s.

Stereologic estimation of breast tumor size

Ladekarl, M., Jensen, V. & Nielsen, B., 1996, I: Analytical and quantitative cytology and histology. 18, 2, s. 151-157 7 s.

Quantitative histopathology in lymph node-negative breast cancer. Prognostic significance of mitotic counts

Ladekarl, M. & Jensen, V., nov. 1995, I: Virchows Archiv. 427, 3, s. 265-270 6 s.

Objective malignancy grading of squamous cell carcinoma of the lung. Stereologic estimates of mean nuclear size are of prognostic value, independent of clinical stage of disease

Ladekarl, M., Boek-Hansen, T., Henrik-Nielsen, R., Mouritzen, C., Henriques, U. & Sørensen, F. B., 1 sep. 1995, I: Cancer. 76, 5, s. 797-802 6 s.

The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer

Jensen, V., Ladekarl, M., Holm-Nielsen, P., Melsen, F. & Sørensen, F. B., aug. 1995, I: Journal of Pathology. 176, 4, s. 343-352 10 s.

Quantitative histopathology in ductal carcinoma of the breast. Prognostic value of mean nuclear size and mitotic counts

Ladekarl, M., 15 apr. 1995, I: Cancer. 75, 8, s. 2114-2122 9 s.

Significance of variations in section mounting technique for nuclear stereology and morphology in urinary bladder neoplasms

Ladekarl, M. & Svanholm, H., mar. 1995, I: APMIS. 103, 7-8, s. 892-896 5 s.

Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer  
Jensen, V. & Ladekarl, M., 1995, I: Journal of Clinical Pathology. 48, 5, s. 429-432 4 s.

The influence of tissue processing on quantitative histopathology in breast cancer  
Ladekarl, M., maj 1994, I: Journal of Microscopy. 174, 2, s. 93-100 8 s.

Reproducibility of mean nuclear volume and correlation with mean nuclear area in breast cancer: An investigation of various sampling schemes  
Baak, J. P. A., Ladekarl, M. & Sørensen, F. B., jan. 1994, I: Human Pathology. 25, 1, s. 80-85 6 s.

Quantitative histopathological variables in in situ and invasive ductal and lobular carcinomas of the breast  
Ladekarl, M. & Sørensen, F. B., dec. 1993, I: APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 101, 12, s. 895-903 9 s.

Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast  
Ladekarl, M. & Sørensen, F. B., 1 nov. 1993, I: Cancer. 72, 9, s. 2602-2611 10 s.

Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas  
Sørensen, F. B., Gamel, J. W., Jensen, O. A., Ladekarl, M. & McCurdy, J., maj 1993, I: APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 101, 5, s. 358-68 11 s.

## Presse/medie

### 10 afklarende svar fra kræftlægen

Morten Ladekarl

28/05/2020

1 Mediebidrag

### Behandling af kræft i bugspytkirtlen

Morten Ladekarl

07/10/2022

1 element af Mediedækning

### Danske kræftafdelinger behandler bugspytkirtelkræft forskelligt, og det påvirker levetiden

Morten Ladekarl

16/03/2022 → 23/03/2022

4 elementer af Mediedækning

### Endnu en KRAS-hæmmer: Lovende effekt mod ikke-småcellet lungekræft

Morten Ladekarl

13/04/2021

1 element af Mediedækning

### Flere kræftpatienter vil have gavn af upfront gensekventering

Morten Ladekarl

20/09/2020 → 21/09/2020

2 elementer af Mediedækning

### Formand for kræftlæger: Vi venter stadig på biomarkørernes store gennembrud

Morten Ladekarl

04/12/2019

1 element af Mediedækning

**Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft**  
Morten Ladekarl  
06/07/2020

1 element af Mediedækning

**Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft**  
Morten Ladekarl  
01/09/2020  
2 elementer af Mediedækning

**Første gang nogensinde: KRAS-hæmmer med tydelig effekt**  
Morten Ladekarl  
21/10/2020  
1 element af Mediedækning

**Første overlevelsесresultater for KRAS-hæmmer mod lungekræft er flotte, men**  
Morten Ladekarl  
14/06/2021  
1 element af Mediedækning

**KRAS-hæmmer viser lovende effekt mod tarmkræft**  
Morten Ladekarl  
21/09/2021  
1 element af Mediedækning

**Kræftdødeligheden falder markant i Danmark**  
Morten Ladekarl  
13/06/2023 → 14/06/2023  
2 elementer af Mediedækning

**Kræftens Bekæmpelse uddeler støtte til kræftforskning**  
Morten Ladekarl  
19/08/2020 → 21/08/2020  
4 elementer af Mediedækning

**Kræftlægen har ordet**  
Morten Ladekarl  
28/05/2020  
1 element af Mediedækning

**Læger håber på en ny kategori i kræftbehandlingen**  
Morten Ladekarl  
22/01/2021  
1 element af Mediedækning

**Morten Ladekarl er ny professor i onkologi**  
Morten Ladekarl  
17/01/2019 → 17/01/2019  
2 elementer af Mediedækning

**Nye overlevelsесdata styrker optimisme om KRAS-hæmmer mod lungekræft**  
Morten Ladekarl  
18/05/2022  
1 element af Mediedækning

**Ny metode til screening for kræft i bugspytkirtlen?**

Morten Ladekarl

25/01/2024

1 element af Mediedækning

**Ny metode til screening for kræft i bugspytkirtlen?**

Morten Ladekarl

05/02/2024

1 element af Mediedækning

**Nyt om navne**

Morten Ladekarl

28/01/2019

1 element af Mediedækning

**Nyt studie: KRAS-hæmmer viser igen lovende effekt mod KRAS-muteret NSCLC**

Morten Ladekarl

02/02/2021

1 element af Mediedækning

**Potentielt praksisændrende: Nyt antistof øger overlevelsen mod kræft i mavesæk og mavemund**

Morten Ladekarl

23/01/2023 → 24/01/2023

2 elementer af Mediedækning

**SPØRG OS**

Morten Ladekarl

17/02/2022

1 element af Mediedækning

**Succes med RAS-hæmmer giver håb om en ny kategori af kræftbehandlinger**

Morten Ladekarl

10/01/2021

1 element af Mediedækning

**Sundhedsstyrelsen har sammensat nyt rådgivende panel**

Morten Ladekarl &amp; Tarec Christoffer El-Galaly

02/11/2023

1 element af Mediedækning

**Aalborg Universitetshospital indfører personaliseret kræftbehandling**

Morten Ladekarl

18/11/2020

1 element af Mediedækning

**Projekter****EPIC-1: A phase II Study of Electroporation Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer**

Flak, R. V., Ladekarl, M., Poulsen, L. Ø., Thorlacius-Ussing, O., Stender, M. T., Detlefsen, S., Agger, R., Kofod-Olsen, E. &amp; Wanders, A.

01/01/2021 → 31/12/2025

**Research profile**

Clinical trials; targeted therapy; genomics; diagnostics; cancer immunology, pathology and epidemiology; gastrointestinal and rare cancers.

## **Leadership**

Professor in oncology and precision medicine, Aalborg (2019-). Former head of GI cancer section and Unit for Experimental Cancer Treatment, Aarhus University Hospital. Member of NBH expert committee for experimental cancer treatment (2015-). Member of Danish Medical Medicines Councils advisory board (2014-). Board member of national multidisciplinary groups for pancreatic, hepato-biliary and gastro-esophageal tumors. Member of the Danish Comprehensive Cancer Center steering committee (2021-), and the ctDNA Center steering committee (2020-). Member of National Genome Center advisory boards (2021-). Chair of one international and three regional scientific meetings.

## **Current clinical trials**

PI of Proseq study of personalized medicine EPIC-1 trial (NCT04835402) of immunotherapy in pancreatic cancer Pantax Ib trial (NCT04652206) targeting therapy resistance in pancreatic cancer DPCG-01 randomized trial of chemotherapy in fragile patients with pancreatic cancer.

### Supervisor and Examiner Responsibilities

Prior supervisor for 2 PhD-students at Health, University of Aarhus. Current supervisor for 3 PhD-students at Health, University of Aalborg. Member/head of the evaluation committee for 7 PhD and 2 doctoral dissertations.

## **Application reviews**

Protocol reviews for EORTC, the Dutch Research Council (NWO) and EU.

## **Research grants**

Active grants from Danish Cancer Society, Danish Regions, Brogaards Foundation, Scandion Oncology A/S, and the NBH.

## **Scientific Journal Involvement**

Member of reviewer board for Journal of Cancers. Advisory board member of Framingham on HCC (2008-12). Guest editor for Scientific World Journal (2012) and Journal of Clinical Medicine (2021). More than 37 peer reviews for at least 14 different international journals.